Diabetic retinopathy: Looking forward to 2030.

Tan TE, Wong TY. · 2022

Read Diabetic retinopathy: Looking forward to 2030. by Tan TE, Wong TY. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9868457.txt.

Introduction

Tan and Wong look ahead to how diabetic retinopathy care may change by 2030. Diabetic retinopathy is the main eye complication of diabetes and a major global health problem. Imaging with optical coherence tomography and anti-VEGF treatment already changed care in recent decades.

The authors expect disease burden to grow and shift toward middle- and low-income regions. They foresee more focus on nerve damage and non-vascular parts of the disease. New imaging, such as widefield systems and OCT angiography, should add richer data. Artificial intelligence should aid screening, diagnosis, and prognosis. New drugs, gene therapy, and updated classification systems round out the outlook.

Catalog record

CREATORTan TE, Wong TY.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9868457

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Diabetic retinopathy: Looking forward to 2030 By Tien-En Tan, Tien Yin Wong Published in: Frontiers in Endocrinology DOI: 10.3389/fendo.2022.1077669 ABSTRACT Abstract Diabetic retinopathy (DR) is the major ocular complication of diabetes mellitus, and is a problem with significant global health impact. Major advances in diagnostics, technology and treatment have already revolutionized how we manage DR in the early part of the 21st century. For example, the accessibility of imaging with optical coherence tomography, and the development of anti-vascular endothelial growth factor (VEGF) treatment are just some of the landmark developments that have shaped the DR landscape over the last few decades. Yet, there are still more exciting advances being made. Looking forward to 2030, many of these ongoing developments are likely to further transform the field. First, epidemiologic projections show that the global burden of DR is not only increasing, but also shifting from high-income countries towards middle- and low-income areas. Second, better understanding of disease pathophysiology is placing greater emphasis on retinal neural dysfunction and non-vascular aspects of diabetic retinal disease. Third, a wealth of information is becoming available from newer imaging modalities such as widefield imaging systems and optical coherence tomography angiography. Fourth, artificial intelligence for screening, diagnosis and prognostication of DR will become increasingly accessible and important. Fifth, new pharmacologic agents targeting other non-VEGF-driven pathways, and novel therapeutic strategies such as gene therapy are being developed for DR. Finally, the classification system for diabetic retinal disease will need to be continually updated to keep pace with new developments. In this article, we discuss these major trends in DR that we expect to see in 2030 and beyond. Keywords: diabetic retinopathy, future trends and predictions, epidemiology, pathophysiology, imaging modalities, artificial intelligence, new treatments, classification and staging system 1 INTRODUCTION Diabetic retinopathy (DR) is the major ocular complication of diabetes mellitus, and occurs in about 30 to 40% of diabetic individuals (1, 2). Globally, more than 100 million individuals are living with DR, and DR is a leading cause of blindness and visual impairment, especially among the working-age adult population (1, 3). Fortunately, much of the visual loss from DR is preventable, and the rates of vision loss from diabetes and DR have steadily declined over the past few decades (4, 5). Such improvements in visual outcomes for DR are multifactorial, and are due in large part to a combination of better systemic risk factor control, coupled with advances in ocular disease assessment, screening, imaging and treatment in recent years. For example, the universal adoption of DR classification systems such as the Early Treatment of Diabetic Retinopathy Study (ETDRS) and International Classification of Diabetic Retinopathy (ICDR) severity scales that effectively prognosticate the risk of disease progression, coupled with large-scale DR screening programs around the world, have allowed for appropriate surveillance and early intervention to prevent the onset of vision-threatening complications (5–7). Panretinal laser photocoagulation (PRP) helps to prevent severe vision loss due to proliferative DR (PDR), and the introduction of pattern scan laser (PASCAL) has made the procedure quicker, easier to perform, and more comfortable for patients (8–10). The widespread availability and use of non-invasive imaging such as optical coherence tomography (OCT), together with the introduction of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatments have revolutionized the assessment and treatment of diabetic macular edema (DME), and dramatically improved visual outcomes for this complication of DR (11–13). Surgical outcomes for tractional retinal detachments and diabetic vitrectomies have also improved over the years, with the availability of more advanced instrumentation and surgical adjuncts such as pre-operative anti-VEGF injections (14–16). Despite the tremendous progress that the field of DR has already seen, there are yet more exciting advances being made. Looking forward over the next decade, many of these ongoing developments are likely to further transform the clinical and research landscapes. In this article, we review some of the recent progress that has been made, and suggest how these developments may continue to shape the field in 2030 and beyond. 2 SHIFTS IN EPIDEMIOLOGY AND DISEASE BURDEN The global prevalence and disease burden of DR is expected to increase significantly over the next few decades, from about 103 million individuals in 2020, to 130 million in 2030, and 161 million in 2045 (17). Such projections are due to a variety of factors, including the increasing prevalence of diabetes around the world, lifestyle changes, and increasing lifespans and aging global populations (17). This sharp increase in DR disease burden by more than 25% in just 10 years, is likely to further strain healthcare systems and resources that are already stretched. The economic costs associated with DR and its complications are substantial. Direct healthcare costs related to DR in the USA were estimated at $493 million per year in 2004 (18). More recent data is lacking, but it is notable that these estimates were arrived at prior to the introduction of anti-VEGF treatment for DME. Subsequent studies have found that economic costs are significantly higher for patients with DME than without, and much of this is due to the need for costly anti-VEGF treatment (19, 20). Global prevalence of DME is also projected by increase by about 25%, to about 24 million individuals by 2030 (17). The resultant increase in healthcare costs are expected to be staggering. Perhaps just as important as the overall increase in disease burden, is the projected pattern of increase. Based on epidemiologic projections to 2030, the rates of increase in DR prevalence for traditionally high-income regions such as North America and Europe appear to be relatively low, ranging from 10.8 to 18.0%. In contrast, the rates of increase in middle- and low-income regions such as the Western Pacific (WP), South and Central America, Asia, Africa, the Middle East and North Africa (MENA) are much higher, ranging from 20.6% to as high as 47.2%. In absolute terms, the largest increases by far are projected to occur in MENA, and WP, where the numbers of individuals with DR are expected to rise by more than 6 million in each region respectively (17). This geographic shift in disease burden towards Asia, Africa and WP means that global health strategies to combat DR will need to pivot to follow the shifting disease demographic. Healthcare resources for DR screening, diagnosis, follow-up, and treatment are urgently needed in these areas. Large-scale systematic, rather than opportunistic, DR screening programs that target all patients with diabetes in these regions will allow for early detection and intervention, will be cost-effective, and will reduce rates of vision loss, but they require significant investment in infrastructure and time to set up (21–24). 3 NON-VASCULAR ASPECTS OF DIABETIC RETINAL DISEASE The clinically-visible retinal lesions associated with DR, such as microaneurysms, hemorrhages and hard exudates, are primarily the result of retinal microvascular damage. Consequently, the focus on DR pathophysiology, diagnosis and assessment has traditionally always centered around the vascular aspect of the disease. However, with the availability of better structural retinal imaging modalities and functional assessments, evidence has accumulated over the years of significant retinal neural dysfunction as well, which occurs together with, or in some cases precedes, the development of vascular abnormalities. These structural and functional changes have collectively been termed “diabetic retinal neurodegeneration” (DRN) (25–28). OCT studies have shown that

Read the complete text